An embodiment of a system includes a power source and at least two electrode assembles. The power source that an output current that alternates between a maximum current value and a minimum current value; a pair of electrode assemblies. Each electrode assembly is configured to be held in contact with a skin layer of a user. Additionally, each electrode assembly includes an electrode that is coupled to the power source to receive the output current from the power source. At least one of the electrode assemblies in the pair includes a medium that carries an active agent having a charge, the medium being provided on the at least one electrode assembly to enable the output current to repel the active agent into the skin layer for a duration in which the output current has a polarity that is the same as a polarity of the active agent.

The present invention relates to a device, comprising: an agent carrier comprising an agent transfer surface for delivery of an agent into a tissue, wherein the agent carrier comprises or is acoustically couplable to a piezoelectric substrate; an electrode electrically couplable to the piezoelectric substrate; and a controller electrically couplable to the electrode and configured to apply an electrical signal to the electrode to propagate an acoustic wave on and/or in the piezoelectric substrate which is capable of delivering the agent from the device into the tissue. Methods of using the device for non-invasive delivery of agents into target tissues are also disclosed.

In a method for enhancing localized delivery of a diagnostic or therapeutic agent using focused ultrasound (FUS), ultrasound-controllable drug carriers are administered into a blood vessel. Each drug carrier comprises an ultrasound-sensitive microbubble loaded with the diagnostic or therapeutic agent. The drug carriers are aggregated inside the vessel both along a radial direction and a longitudinal direction by application of an aggregation FUS sequence. Subsequently the diagnostic or therapeutic agent is released from the drug carriers by application of an uncaging FUS sequence. The aggregation and uncaging sequences are applied using FUS below a threshold power level such that harmful cavitation is avoided, as evidenced by the absence of broadband emissions and preferably non-integer harmonics from an emission spectrum of the drug carriers. Thereby damage to the vasculature by the FUS sequence is avoided. The method can in particular be employed to deliver drugs to the brain without opening the blood-brain barrier.

A device for magnetic drug targeting, comprising: a magnetic element (3) for providing a magnetic field configured to retain magnetic microbubbles within a target volume; an ultrasound element (2) for providing an acoustic field configured to excite the magnetic microbubbles while the magnetic microbubbles are retained by the magnetic field within the target volume.

The systems and methods disclosed herein relate generally to microbubble-assisted delivery of a therapeutic agent, such as a chemotherapeutic agent, to cells or tissue of interest, either in vitro or in vivo, that can be activated by directed ultrasound irradiation. For example, hydrophobic sonosensitizers can be incorporated in microbubble complexes to provide improved sonodynamic therapies.

Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

A phonophoretic cannabidiol composition comprises an amount of cannabidiol, an amount of a glucose source, such as honey, an amount of aloe vera, and amounts of one or more of glucosamine, methylsulfonylmethane, and chondroitin. A transdermal delivery system for administration of a phonophoretic cannabidiol composition includes a phonophoretic cannabidiol composition, a laser generator comprising an emitter which generates and directs a laser beam to the treatment area, and an ultrasound generator comprising a transducer which generates and transmits a plurality of ultrasonic waves to the treatment area. A method for transdermal delivery of a phonophoretic cannabidiol composition includes selecting laser pretreatment parameters, directing a laser beam to the treatment area, applying an amount of a phonophoretic cannabidiol composition to a treatment area, selecting ultrasonic treatment parameters, and, transmitting a plurality of ultrasonic waves to the treatment area.

Provided herein are non-plasmid derived DNA vaccines comprised solely of enzymatically produced amplicon expression vectors and their method of use to elicit antigen-specific immune responses in a subject. The enzymatically produced amplicon expression vectors may be specifically utilized as a DNA based cancer vaccine to express desired antigens or other immunogenic polypeptides within a subject to induce a specific anti-cancer antigen-specific immune response. The enzymatically produced amplicon expression vectors may also be utilized to express cancer-specific neoantigens.

The present invention refers to the transporation, or force-transdermal vehiculation, of cyanobacterial algae or extracts thereof, through electroporation, sonoporation (sound), photoporation (light), radioporation (radio frequency), and through any other transporation tool for enhancing the transdermal penetration of cyanobacterial molecules via the transmission of some force, be it electric, or generated by sound, light and/or radio frequencies. The invention cover the use of whole cyanobacterial algae or extracts thereof, with different levels of transdermal penetration, be it the low intensity transporation, which can be used for deep aesthetic and skin regenerating purposes, as well as dermatological problems; or the high intensity transporation, able to penetrate deep though the dermis, and beyond the hypodermis into organs and tissues, and that can be uses for muscular, osteo-articular and metabolic problems. Following an exhaustive explanation of the invention, we present very significant results in different beauty and health areas.